Routine Neutral

2026-07-14 11:55

New Filing detected. See link for details.

Governance Neutral

2026-07-14 09:58

CRITICAL RED FLAG DETECTED

- Natco Pharma received an order from Asst. Commissioner (ST) imposing a tax demand, interest, and penalty totaling ~₹59.87 lakhs for under-reporting Reverse Charge Mechanism (RCM) in GSTR 3B during FY20-24. The company states there is no material impact on its operations and is evaluating the matter.

Business Update Positive

2026-07-08 12:06

- Board approved an investment of ₹1400 Crores in Natco Pharma South Africa Proprietary Limited, a wholly-owned subsidiary of the company. - Board approved acquiring 19,618,825 shares in Adcock Ingram Holdings Proprietary Limited for ₹1069 crores (ZAR 1.8 billion), increasing its stake from 35.75% to 49%. - The objective is to expand geographic footprint, growth, and profitability in South Africa and the continent of Africa. - Adcock Ingram reported a topline of US$ 423 million and EBITDA of ~US$ 59 million for the 9 months ending March 31, 2026.

Governance Positive

2026-07-06 17:49

- Natco Pharma Limited designated Mr. Gnanadeva Chalapathy Gudipati as Senior VP - Analytical R&D and Mr. Madhava Rao Karicherla as VP - Formulation R&D, Pharma Division, Kothur Unit, effective July 6, 2026, strengthening the management team.

Governance Neutral

2026-06-30 16:21

- Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division - Kothur of Natco Pharma Limited, has superannuated. - His cessation is effective from the closure of business hours on 30th June, 2026.

Routine Neutral

2026-06-30 16:17

- Trading window for dealing in company securities will close from July 1, 2026. - It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The date of the board meeting for results will be intimated in due course.

Business Update Negative

2026-06-04 15:02

CRITICAL RED FLAG DETECTED

- FY27 Consolidated Revenue guidance: INR 3,400-3,500 crores. - FY27 Consolidated PAT guidance: INR 700-750 crores, a significant contraction from FY26. - The company acknowledges a 'muted' FY27 with a dip in earnings due to competitive pressures, particularly from Revlimid. - Growth drivers include diversification into Brazil (projected to reach INR 450-500 crores in FY27) and Canada (10-15% growth), and the Adcock Ingram acquisition in South Africa. - Semaglutide vial launch in India is targeted for INR 75-100 crores annualized revenue. - Company holds INR 2,400 crores net cash and is actively seeking M&A opportunities, primarily outside India. - R&D spend is expected to be 7-9% of revenue for FY27, focusing on complex and first-to-file products. - Management expects earnings to compound 15-25% annually from FY28 onwards, driven by new exclusivities and diversified portfolio. - Aiming to reduce earnings volatility by having base revenue contribute 70% of profit, and special products 25-30% within 5 years.

Business Update Positive

2026-06-03 11:16

- NATCO Pharma Limited and its alliance partner Lupin Limited received approval from the U.S. FDA for NATCO's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) Single-Dose Vials. - The injection is bioequivalent to the reference listed drug Halaven® Injection of Eisai, Inc. - It is indicated for the treatment of adults with metastatic breast cancer and unresectable or metastatic liposarcoma. - The Reference Listed Drug (RLD) Halaven® had estimated annual sales of USD 43.7 million in the U.S.

Business Update Neutral

2026-05-30 12:21

Natco Pharma Limited submitted the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is enclosed and also available on the company's website.

Financials Negative

2026-05-29 15:32

Consolidated Revenue ₹8,169 Mn vs ₹12,873 Mn (▼36.5% YoY), EBITDA ₹2,054 Mn vs ₹6,144 Mn (▼66.6% YoY), PAT ₹2,690 Mn vs ₹4,060 Mn (▼33.7% YoY). EBITDA Margin 25.1% vs 47.7% (▼2260bps).

Financials Negative

2026-05-29 14:22

NATCO Pharma Limited reported consolidated Q4 FY26 results with Total Income of ₹816.9 Cr compared to ₹1,287.3 Cr in Q4 FY25 (▼36.6% YoY). EBITDA was ₹127.6 Cr vs ₹548.1 Cr (▼76.7% YoY). Net Profit (PAT) stood at ₹269.0 Cr vs ₹406.0 Cr (▼33.7% YoY). EBITDA Margin significantly contracted to 15.6% from 42.6% (▼2700bps). Q4 FY26 PAT includes a one-time deferred tax asset benefit of ₹115.0 Cr.

Business Update Neutral

2026-05-21 12:29

Natco Pharma Limited will host an earnings call for investors and analysts on Friday, May 29, 2026, at 4:30 PM IST. The call, hosted by 360 ONE Capital Market Private Limited, will discuss the company's Audited Financial Results for the quarter and year ended March 31, 2026. Key management, including the Vice-chairman and CEO, CFO, and EVP, Crop Health Sciences, will participate.

Business Update Negative

2026-05-14 16:19

CRITICAL RED FLAG DETECTED

Natco Pharma Limited received a demand notice on May 12, 2026, from the National Pharmaceutical Pricing Authority. The notice directs the company to deposit ₹4,92,25,923/-, including overcharge, penalty, and interest, for allegedly overcharging on two drugs between April 2023 and November 2023. The company stated there is no material impact on its financial, operational, or other activities.

Routine Neutral

2026-04-09 10:52

Natco Pharma Limited submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026, confirming securities received for dematerialization were processed and depository records updated.

Routine Neutral

2026-03-31 13:58

Natco Pharma Ltd. announced the closure of the trading window for Directors, Designated Persons, and connected persons from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ending March 31, 2026. The date of the Board Meeting will be intimated in due course.

Governance Positive

2026-03-25 15:44

Natco Pharma announced the results of its postal ballot held from February 12 to March 24, 2026. All resolutions were passed with requisite majority, confirming the re-appointment of Sri V. C. Nannapaneni as Chairman & MD, Sri Rajeev Nannapaneni as Vice Chairman & CEO, and two other directors with effect from April 1, 2026.

Governance Positive

2026-03-24 17:16

Natco Pharma's board approved demerging its Agrochemicals Business into Natco Crop Health Sciences Ltd, effective October 1, 2026. Shareholders get 1 share of the new entity for every 1 held. Also approved: forming a Nigerian subsidiary and liquidating an Australian one.

Business Update Positive

2026-03-20 09:32

Natco Pharma launched Semaglutide Generic Injection multi-dose vials in India on March 20, 2026, at an affordable price starting from INR 1,290 per month. It's the first to offer this GLP-1 therapy in vial form, making it significantly cheaper than innovator brands.

Business Update Neutral

2026-03-06 10:25

Natco Pharma Limited announced participation in the Investec Promoter and Founder Conference 2026 on March 9, 2026, in Mumbai. No Unpublished Price Sensitive Information will be discussed during the meeting.

Business Update Positive

2026-03-03 10:31

NATCO Pharma Limited announced on March 3, 2026, the launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market, in partnership with Breckenridge Pharmaceutical, Inc. The generic drug targets multiple myeloma and AIDS-related Kaposi sarcoma. Pomalidomide Capsules had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep '25.

Business Update Positive

2026-02-25 10:02

Natco Pharma confirmed receiving CDSCO approval for Semaglutide in India on Feb 14, 2026. The company plans to launch the product with marketing partners, including Eris Lifesciences Ltd, in March 2026. They stated the partnership has no material financial impact.

Routine Neutral

2026-02-24 16:55

New Filing detected. See link for details.

Governance Neutral

2026-02-20 13:03

Natco Pharma announced a Postal Ballot to seek shareholder approval for the re-appointment of four directors, including Chairman & MD V.C. Nannapaneni and Vice Chairman & CEO Rajeev Nannapaneni, for a period of one year from April 1, 2026 to March 31, 2027. E-voting will take place from February 23 to March 24, 2026, with results declared by March 26, 2026.

Financials Positive

2026-02-18 15:36

Consolidated Revenue ₹705.4Cr vs ₹651.1Cr (▲8.3% YoY). For the quarter ended December 31, 2025, EBITDA was ₹216.8Cr and Net Profit was ₹151.3Cr. EBITDA Margin stood at 30.7%. An interim dividend of INR 1.5 per share was declared.

Business Update Positive

2026-02-14 09:32

NATCO Pharma Limited received approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. This product, for type 2 diabetes, is scheduled for launch in the Indian market by March 2026.

Business Update Positive

2026-02-13 09:19

Natco Pharma Limited's API unit in Chennai received an Establishment Inspection Report (EIR) from the U.S. FDA, classifying the inspection as Voluntary Action Indicated (VAI). The inspection, held November 17-21, 2025, had 7 Form 483 observations.

Business Update Neutral

2026-02-12 18:04

Natco Pharma Limited informed about the uploading of the audio recording of its Q3 FY25-26 earnings conference call, held on February 12, 2026, to the company's website. The recording is available for access by investors.

Financials Positive

2026-02-12 15:50

Natco Pharma Limited declared a 3rd interim dividend of Rs. 1.50/- (75%) per equity share for FY 2025-26. The record date for eligibility is Wednesday, February 18, 2026, with payment commencing from February 26, 2026.

Business Update Positive

2026-02-12 15:49

On February 12, 2026, Natco Pharma Limited's Board approved the incorporation of a wholly-owned subsidiary, NATCO Pharma Chile SPA, in Chile, with an investment not exceeding US$300,000, to engage in the pharmaceuticals business.

Governance Positive

2026-02-12 15:46

CRITICAL RED FLAG DETECTED

NATCO Pharma announced Mr. S.V.V.N. Appa Rao's superannuation as CFO on Feb 12, 2026. Mr. Amit Parekh was appointed as the new CFO from Feb 13, 2026. Additionally, Mr. Kalakuntla Srinivas Rao was appointed Executive Vice President – Pharma Division from Feb 12, 2026, strengthening the leadership team.

Governance Positive

2026-02-12 15:46

NATCO Pharma announced the superannuation of its CFO, Mr. S.V.V.N. Appa Rao, on Feb 12, 2026. Mr. Amit Parekh was appointed as the new CFO (effective Feb 13, 2026), and Mr. Kalakuntla Srinivas Rao as EVP – Pharma Division, bringing extensive industry experience.

Governance Neutral

2026-02-12 15:46

Natco Pharma announced CFO Mr. S.V.V.N. Appa Rao's superannuation on Feb 12, 2026. Mr. Amit Parekh is appointed as the new CFO from Feb 13, 2026. Mr. Kalakuntla Srinivas Rao also appointed EVP – Pharma Division from Feb 12, 2026.

Financials Positive

2026-02-12 15:03

Consolidated Revenue ₹7,054 Mn vs ₹6,511 Mn (▲8.34% YoY). Q3FY26 EBITDA ₹2,168 Mn, PAT ₹1,513 Mn. EBITDA Margin 30.7%.

Financials Positive

2026-02-12 14:41

Consolidated Revenue ₹647.3Cr vs ₹474.8Cr (▲36.3% YoY), EBITDA ₹158.7Cr vs ₹38.8Cr (▲309.0% YoY), PAT ₹151.5Cr vs ₹133.0Cr (▲13.9% YoY). EBITDA Margin 24.5% vs 8.2% (▲1630bps).

Financials Positive

2026-02-12 14:33

Consolidated Revenue ₹647.3Cr vs ₹474.8Cr (▲36.3% YoY), EBITDA ₹158.7Cr vs ₹38.8Cr (▲309.0% YoY), PAT ₹151.3Cr vs ₹132.4Cr (▲14.3% YoY). EBITDA Margin 24.5% vs 8.2% (▲1630bps). The company also declared an interim dividend of ₹1.50 per equity share and approved the incorporation of a new subsidiary in Chile.

NATCOPHARM

Natco Pharma Limited

Price Chart

Filing History

Unlock Full History